Scienture Holdings (SCNX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 Sep, 2026Executive summary
Annual meeting scheduled for October 28, 2026, to be held virtually, with record date set as September 11, 2026.
Key proposals include election of five directors, ratification of auditor, advisory vote on executive compensation, and potential adjournment to solicit additional proxies.
Proxy materials are available online, and shareholders can vote via mail, internet, or telephone.
Company reported significant revenue growth and improved financial position in the first half of 2026, with reduced operating expenses and narrowed net losses.
Voting matters and shareholder proposals
Shareholders will vote on electing five directors, ratifying CM3 Advisory as auditor, approving executive compensation (say-on-pay), and authorizing adjournment if needed.
No cumulative voting or appraisal rights apply to these proposals.
Board recommends voting “FOR” all proposals.
No shareholder proposals were received for this meeting.
Board of directors and corporate governance
Board consists of five members, with a majority being independent.
Committees include audit, compensation, and nominating/governance, all chaired by independent directors.
Board and committees met regularly, with high attendance and executive sessions held without management.
Board leadership combines Executive Chairman and Co-CEO roles for clarity and efficiency.
Director nominations consider diversity in experience, skills, and background.
Latest events from Scienture Holdings
- Two new therapies launched in 2026 drive revenue growth, with a strong pipeline and expanding coverage.SCNX
H.C. Wainwright 28th Annual Global Investment Conference - Rapid revenue growth and FDA-approved launches highlight a strong specialty pharma pipeline.SCNX
Corporate presentation - 2026 meeting covers director elections, auditor ratification, and executive pay, with strong governance.SCNX
Proxy filing - Q2 2026 revenue surged 510% on ARBLI™ sales, with net loss narrowing and strong liquidity maintained.SCNX
Q2 2026 - Two FDA-approved launches and a robust pipeline drive revenue growth and near-term profitability.SCNX
WTR Insights Conference: Powered by The Small Cap Showcase - Revenue fell sharply in Q3 2024 as the company shifted focus to pharma R&D and paid large dividends.SCNX
Q3 2024 - Specialty pharma pivot with high R&D spend, ongoing losses, and up to $50M ELOC funding planned.SCNX
Registration filing - Biopharma pivots to CNS/CVS drugs, seeks $50M equity, faces losses, dilution, and regulatory risk.SCNX
Registration filing - Clinical-stage pharma seeks $50M equity to fund pipeline amid ongoing losses and high risk.SCNX
Registration filing